Pars Planitis Treatment Market Report 2026

Pars Planitis Treatment Market Overview

• Pars Planitis Treatment market size has reached to $683.54 billion in 2025 • Expected to grow to $989.53 billion in 2030 at a compound annual growth rate (CAGR) of 7.6% • Growth Driver: Increasing Prevalence Of Pars Planitis Fueling The Growth Of The Market Due To Advancements In Diagnosis And Rising Awareness • Market Trend: Bispecific Antibodies Offer Dual Targeting For Enhanced Eye Inflammation Control • North America was the largest region in 2025.

What Is Covered Under Pars Planitis Treatment Market?

Pars planitis treatment involves medical and surgical interventions aimed at managing pars planitis, a chronic, intermediate uveitis condition that affects the pars plana region of the eye, leading to inflammation and potential vision impairment. The primary goal of treatment is to reduce ocular inflammation, prevent complications such as macular edema or retinal detachment, and preserve visual function. The main treatment types of pars planitis treatment are corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), surgery, cryotherapy, immunomodulatory therapy, and others. Corticosteroids refer to anti-inflammatory medications that mimic hormones produced by the adrenal glands to reduce swelling, suppress the immune system, and manage inflammation-related conditions. The diagnosis methods comprise blood tests, X-rays, magnetic resonance imaging (MRI), and others, and are administered orally, intravenously, and others. These are distributed through various distribution channels, including hospital pharmacy, retail pharmacy, and online pharmacy, serving a range of end users, including clinics, hospitals, and others.

What Is The Pars Planitis Treatment Market Growth Forecast?

The pars planitis treatment market size is expected to see strong growth in the next few years. It will grow to $989.53 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing adoption of personalized ophthalmic treatments, rising demand for long-term inflammation control, expansion of biologic drug pipelines, growing focus on vision preservation strategies, increasing investment in advanced ophthalmic diagnostics. Major trends in the forecast period include increasing use of immunomodulatory therapies, rising adoption of biologic agents, growing preference for targeted anti-inflammatory treatments, expansion of advanced ocular surgical techniques, enhanced focus on early diagnosis and disease monitoring.

Global Pars Planitis Treatment Market Segmentation

1) By Treatment: Corticosteroid, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Surgery, Cryotherapy, Immunomodulatory Therapy, Other Treatments 2) By Diagnosis: Blood Tests, Fundus Examination And Optical Coherence Tomography, Magnetic Resonance Imaging (MRI), Other Diagnosis 3) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 5) By End-User: Clinic, Hospital, Other End-Users Subsegments: 1) By Corticosteroid: Topical Corticosteroids, Periocular Corticosteroid Injections, Intravitreal Corticosteroid Implants, Systemic Corticosteroids 2) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Injectable Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 3) By Surgery: Pars Plana Vitrectomy, Cataract Surgery, Glaucoma Surgery 4) By Cryotherapy: Trans-scleral Cryotherapy, Endocryotherapy 5) By Immunomodulatory Therapy: Antimetabolites, Calcineurin Inhibitors, Biologic Agents 6) By Other Treatments: Antibiotics, Antivirals, Laser therapy

What Is The Driver Of The Pars Planitis Treatment Market?

The increasing prevalence of pars planitis is expected to propel the growth of the pars planitis treatment market going forward. Pars planitis refers to an idiopathic form of intermediate uveitis that primarily causes inflammation in the vitreous and peripheral retina, typically affecting individuals aged 15 to 40. The increasing prevalence of pars planitis is due to growing awareness and improved diagnostic capabilities as advanced imaging tools enable earlier and more accurate detection. Pars planitis treatments help manage pars planitis by reducing ocular inflammation, making them essential for preserving vision and preventing complications. They enhance patient care by offering targeted therapies such as corticosteroids and immunosuppressants, improving long-term eye health and quality of life. For instance, in February 2025, according to a case report published by Mega Journal of Case Reports, a US-based medical journal, intermediate uveitis occurs at a rate of 1.4 to 2 cases per 100,000 people, with the idiopathic form, pars planitis, accounting for 70% of the cases. Therefore, the increasing prevalence of pars planitis is driving the growth of the pars planitis treatment industry.

Key Players In The Global Pars Planitis Treatment Market

Major companies operating in the pars planitis treatment market are Johnson And Johnson, Merck And Co Inc, AbbVie Inc, Bayer AG, AstraZeneca plc, Novartis AG, EyePoint Pharmaceuticals Inc, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd, Quantum Cryogenics Ltd, Zimmer MedizinSysteme GmbH, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Limited, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Clearside Biomedical Inc, Roche Holding AG, Pfizer Inc, Bristol Myers Squibb Company, Regeneron Pharmaceuticals Inc, UCB SA, Bausch Health Companies Inc

Global Pars Planitis Treatment Market Trends and Insights

Major companies operating in the pars planitis treatment market are focusing on developing innovative solutions, such as bispecific antibodies, to enhance immune modulation, reduce ocular inflammation, and minimize systemic side effects. Bispecific antibodies are engineered proteins designed to bind to two different antigens or targets simultaneously, offering more precise and effective treatment with fewer side effects. For instance, in October 2023, Genentech Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for Vabysmo (faricimab-svoa) for the treatment of retinal vein occlusion (RVO), in addition to age-related macular degeneration and diabetic macular edema. Vabysmo is the first bispecific antibody for ophthalmic use that targets both Angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), addressing inflammation and vascular leakage simultaneously. This innovative mechanism is being explored for use in intermediate uveitis, including pars planitis, where chronic inflammation in the retinal periphery requires durable and targeted intervention.

What Are Latest Mergers And Acquisitions In The Pars Planitis Treatment Market?

In May 2023, Alimera Sciences, a US-based healthcare/pharmaceutical company, acquired the U.S. commercial rights to YUTIQ from EyePoint Pharmaceuticals, Inc. for an undisclosed amount. With this acquisition, Alimera aimed to expand and consolidate its U.S. retinal-disease portfolio and leverage its existing commercial infrastructure to drive product utilisation, revenue growth and deeper market penetration of sustained-release ophthalmic therapies. EyePoint Pharmaceuticals Inc., is a US-based biopharmaceutical company that specialises in ophthalmic drug-delivery technologies and developed YUTIQ.

Regional Outlook

North America was the largest region in the pars planitis treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pars Planitis Treatment Market?

The pars planitis treatment market consists of revenues earned by entities by providing services such as diagnosis, pharmacological therapies, surgical interventions, and supportive care management. The market value includes the value of related goods sold by the service provider or included within the service offering. The pars planitis treatment market also includes sales of immunosuppressants, intraocular steroid implants, surgical equipment, and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pars Planitis Treatment Market Report 2026?

The pars planitis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pars planitis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.